E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with metastatic breast cancer, newly found on 18F-FDG PET/CT, with or without HER2/neu overexpression or amplification (n=5) of one of the biopsied lesions. |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with breast cancer beyond the breast and lymph nodes. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Use 89Zr-Trastuzumab to characterise the in vivo biodistribution of Zr89-Trastuzumab using PET imaging in the primary tumour and distant metastases, and comparing patients with Her2/neu positive breast cancer to patients with HER2/neu negative breast cancer. |
|
E.2.2 | Secondary objectives of the trial |
Compare the 89Zirconium tracer uptake within the primary tumour and metastases with lesions visualised on the 18F-FDG PET/ CT. And, relate circulating HER2/neu (serum HER2) concentration to 89Zr-Trastuzumab uptake in the tumour. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Histological confirmed breast cancer (5 with and 5 without HER2/neu overexpression or amplification), with a primary tumour and at least 1 distant metastatic lesion.
Recent diagnostic 18F-FDG PET/CT (less than 1 month old) made at the NKI-AvL. |
|
E.4 | Principal exclusion criteria |
A medical condition (e.g. Li-Fraumeni) that would place the patient at unusual risk for development of new malignancies due to radiation. Concurrent use of investigational drug with unknown biodistribution. Present pregnancy, or the patient refuses to use an adequate contraception method if pre-menopausal. Known allergy for murine proteins (present in Trastuzumab). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Describe and quantify the 89Zr-Trastuzumab biodistribution in all patients in terms of heterogeneity, dose per volume (MBq/ml), percentage of injected dose per volume tissue (%ID/ml) and Standardised Uptake Values (SUVs) based on conventional PET/CT and MAMMI PET. Relate 89Zr-Trastuzumab tumour accumulation to 18F-FDG accumulation and Serum HER2 concentration. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The main study endpoint is determined after all acquisitions are made and analysed, comparing the images of HER2/neu positive and breast cancer lesions. with the images of HER2/neu negative breast cancer lesions. |
|
E.5.2 | Secondary end point(s) |
A description of the relation between uptake patterns on 18F-FDG and 89Zr-Trastuzumab PET will be provided. Additionally, the variation of serum HER2 will be related to the Zr-89 Trastuzumab accumulation in the normal tissue and tumour lesions. These data again will provide mean and variation values in Her2/neu positive and negative tumours. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
All endpoint will be analysed after acquisition of all images and obtaining all results from venous blood analyses. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |